Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015 (2015), Article ID 810369, 13 pages
http://dx.doi.org/10.1155/2015/810369
Research Article

Hugan Qingzhi Exerts Anti-Inflammatory Effects in a Rat Model of Nonalcoholic Fatty Liver Disease

1Center for Drug Research and Development, Zhujiang Hospital, Southern Medical University, Guangdong, Guangzhou 510282, China
2Department of Pharmacy, Ganzhou People’s Hospital, Nanchang University, Jiangxi, Ganzhou 341000, China
3Department of Pharmacy, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou 510150, China
4Department of Pharmacy, Beijiao Hospital, Southern Medical University, Guangdong, Guangzhou 528311, China
5Department of Traditional Chinese Medicine, Zhujiang Hospital, Southern Medical University, Guangdong, Guangzhou 510282, China

Received 20 January 2015; Revised 14 May 2015; Accepted 18 May 2015

Academic Editor: Yoshiji Ohta

Copyright © 2015 WaiJiao Tang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Vernon, A. Baranova, and Z. M. Younossi, “Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults,” Alimentary Pharmacology and Therapeutics, vol. 34, no. 3, pp. 274–285, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. A. C. Tuyama and C. Y. Chang, “Non-alcoholic fatty liver disease,” Journal of Diabetes, vol. 4, no. 3, pp. 266–280, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. S. H. Chen, F. He, H. L. Zhou, H. R. Wu, C. Xia, and Y. M. Li, “Relationship between nonalcoholic fatty liver disease and metabolic syndrome,” Journal of Digestive Diseases, vol. 12, no. 2, pp. 125–130, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. C. P. Day, “Non-alcoholic fatty liver disease: current concepts and management strategies,” Clinical Medicine, Journal of the Royal College of Physicians of London, vol. 6, no. 1, pp. 19–25, 2006. View at Google Scholar · View at Scopus
  5. C. L. Gentile and M. J. Pagliassotti, “The role of fatty acids in the development and progression of nonalcoholic fatty liver disease,” The Journal of Nutritional Biochemistry, vol. 19, no. 9, pp. 567–576, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Hug, S. Strand, A. Grambihler et al., “Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells,” The Journal of Biological Chemistry, vol. 272, no. 45, pp. 28191–28193, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. D. G. Tiniakos, M. B. Vos, and E. M. Brunt, “Nonalcoholic fatty liver disease: pathology and pathogenesis,” Annual Review of Pathology: Mechanisms of Disease, vol. 5, pp. 145–171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. R. C. Harmon, D. G. Tiniakos, and C. K. Argo, “Inflammation in nonalcoholic steatohepatitis,” Expert Review of Gastroenterology and Hepatology, vol. 5, no. 2, pp. 189–200, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. S. A. Polyzos, J. Kountouras, C. Zavos, and E. Tsiaousi, “The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease,” Diabetes, Obesity and Metabolism, vol. 12, no. 5, pp. 365–383, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. C. L. Gentile, M. A. Frye, and M. J. Pagliassotti, “Fatty acids and the endoplasmic reticulum in nonalcoholic fatty liver disease,” BioFactors, vol. 37, no. 1, pp. 8–16, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. S. De Minicis and G. Svegliati-Baroni, “Fibrogenesis in nonalcoholic steatohepatitis,” Expert Review of Gastroenterology and Hepatology, vol. 5, no. 2, pp. 179–187, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. K. J. Bitterman, O. Medvedik, and D. A. Sinclair, “Longevity regulation in Saccharomyces cerevisiae: linking metabolism, genome stability, and heterochromatin,” Microbiology and Molecular Biology Reviews, vol. 67, no. 3, pp. 376–399, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. X.-Q. Deng, L.-L. Chen, and N.-X. Li, “The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats,” Liver International, vol. 27, no. 5, pp. 708–715, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. Y.-R. Chen, S.-R. Fang, Y.-C. Fu, X.-H. Zhou, M.-Y. Xu, and W.-C. Xu, “Calorie restriction on insulin resistance and expression of SIRT1 and SIRT4 in rats,” Biochemistry and Cell Biology, vol. 88, no. 4, pp. 715–722, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. F. Zhang, S. H. Fan, Y. L. Zheng et al., “Troxerutin improves hepatic lipid homeostasis by restoring NAD+-depletion-mediated dysfunction of lipin 1 signaling in high-fat diet-treated mice,” Biochemical Pharmacology, vol. 91, no. 1, pp. 74–86, 2014. View at Publisher · View at Google Scholar
  16. J. M. Andrade, A. F. Paraiso, M. V. de Oliveira et al., “Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation,” Nutrition, vol. 30, no. 7-8, pp. 915–919, 2014. View at Publisher · View at Google Scholar
  17. G.-Z. Dong, J.-H. Lee, S. H. Ki et al., “AMPK activation by isorhamnetin protects hepatocytes against oxidative stress and mitochondrial dysfunction,” European Journal of Pharmacology, vol. 740, pp. 634–640, 2014. View at Publisher · View at Google Scholar
  18. F. Picard, M. Kurtev, N. Chung et al., “Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-γ,” Nature, vol. 429, no. 6993, pp. 771–776, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Yu and J. Auwerx, “Protein deacetylation by SIRT1: an emerging key post-translational modification in metabolic regulation,” Pharmacological Research, vol. 62, no. 1, pp. 35–41, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Xie, X. Zhang, and L. Zhang, “Negative regulation of inflammation by SIRT1,” Pharmacological Research, vol. 67, no. 1, pp. 60–67, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Salminen, A. Kauppinen, T. Suuronen, and K. Kaarniranta, “SIRT1 longevity factor suppresses NF-κB-driven immune responses: regulation of aging via NF-κB acetylation?” BioEssays, vol. 30, no. 10, pp. 939–942, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. K.-Q. Shi, Y.-C. Fan, W.-Y. Liu, L.-F. Li, Y.-P. Chen, and M.-H. Zheng, “Traditional Chinese medicines benefit to nonalcoholic fatty liver disease: a systematic review and meta-analysis,” Molecular Biology Reports, vol. 39, no. 10, pp. 9715–9722, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. W.-H. Tsai, C.-C. Yang, P.-C. Li, W.-C. Chen, and C.-T. Chien, “Therapeutic potential of traditional chinese medicine on inflammatory diseases,” Journal of Traditional and Complementary Medicine, vol. 3, no. 3, pp. 142–151, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. W.-H. Park, C.-H. Kim, and Y.-C. Lee, “Anti-inflammatory effects of a traditional Korean herbal formulation, Silsosangami, consisting of seven medicinal herbs: effect on hemolysis, neutrophil function, and gene expressions of iNOS and COX-2,” Vascular Pharmacology, vol. 42, no. 1, pp. 7–15, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Yin, Y. Luo, H. Deng et al., “Hugan Qingzhi medication ameliorates hepatic steatosis by activating AMPK and PPARα pathways in L02 cells and HepG2 cells,” Journal of Ethnopharmacology, vol. 154, no. 1, pp. 229–239, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. W. J. Tang, B. J. Zhou, and H. Zhou, “Pharmacodynamics research of Huganqingzhi tablet on rats with non-alcoholic fatty liver model,” Pharmacology and Clinics of Chinese Materia Medica, vol. 29, pp. 169–172, 2013. View at Google Scholar
  27. B.-J. Zhou, Y.-M. Yan, S.-X. Huang, Y.-F. Yao, and S.-Y. Zhang, “The quality standard study on Hugan qingzhi tablets,” Zhong Yao Cai, vol. 35, no. 4, pp. 644–647, 2012. View at Google Scholar · View at Scopus
  28. Y. S. Seo, J. H. Kim, N. Y. Jo et al., “PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes,” Journal of Gastroenterology and Hepatology, vol. 23, no. 1, pp. 102–109, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. D. E. Kleiner, E. M. Brunt, M. Van Natta et al., “Design and validation of a histological scoring system for nonalcoholic fatty liver disease,” Hepatology, vol. 41, no. 6, pp. 1313–1321, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Ohkawa, N. Ohishi, and K. Yagi, “Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction,” Analytical Biochemistry, vol. 95, no. 2, pp. 351–358, 1979. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Rosso, N. C. Chavez-Tapia, C. Tiribelli et al., “Translational approaches: from fatty liver to non-alcoholic steatohepatitis,” World Journal of Gastroenterology, vol. 20, no. 27, pp. 9038–9049, 2014. View at Google Scholar
  32. H. Tilg and A. R. Moschen, “Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis,” Hepatology, vol. 52, no. 5, pp. 1836–1846, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. M. E. Kotas, M. C. Gorecki, and M. P. Gillum, “Sirtuin-1 is a nutrient-dependent modulator of inflammation,” Adipocyte, vol. 2, no. 2, pp. 113–118, 2013. View at Publisher · View at Google Scholar
  34. Z.-J. Xu, J.-G. Fan, X.-D. Ding, L. Qiao, and G.-L. Wang, “Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats,” Digestive Diseases and Sciences, vol. 55, no. 4, pp. 931–940, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Wojtczak and P. Schonfeld, “Effect of fatty acids on energy coupling processes in mitochondria,” Biochimica et Biophysica Acta, vol. 1183, no. 1, pp. 41–57, 1993. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Carlsson, L. A. H. Borg, and N. Welsh, “Sodium palmitate induces partial mitochondrial uncoupling and reactive oxygen species in rat pancreatic islets in vitro,” Endocrinology, vol. 140, no. 8, pp. 3422–3428, 1999. View at Google Scholar · View at Scopus
  37. S.-I. Yamagishi, D. Edelstein, X.-L. Du, Y. Kaneda, M. Guzmán, and M. Brownlee, “Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A,” The Journal of Biological Chemistry, vol. 276, no. 27, pp. 25096–25100, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. M. S. Rao and J. K. Reddy, “Peroxisomal β-oxidation and steatohepatitis,” Seminars in Liver Disease, vol. 21, no. 1, pp. 43–55, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. J. C. Cohen, J. D. Horton, and H. H. Hobbs, “Human fatty liver disease: old questions and new insights,” Science, vol. 332, no. 6037, pp. 1519–1523, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Colak, O. Ozturk, E. Senates et al., “SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease,” Medical Science Monitor, vol. 17, no. 5, pp. HY5–HY9, 2011. View at Google Scholar · View at Scopus
  41. F. Yeung, J. E. Hoberg, C. S. Ramsey et al., “Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase,” The EMBO Journal, vol. 23, no. 12, pp. 2369–2380, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. J.-H. Lee, M.-Y. Song, E.-K. Song et al., “Overexpression of SIRT1 protects pancreatic β-cells against cytokine toxicity by suppressing the nuclear factor-κB signaling pathway,” Diabetes, vol. 58, no. 2, pp. 344–351, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. P. T. Pfluger, D. Herranz, S. Velasco-Miguel, M. Serrano, and M. H. Tschöp, “Sirt1 protects against high-fat diet-induced metabolic damage,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 28, pp. 9793–9798, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Purushotham, T. T. Schug, Q. Xu, S. Surapureddi, X. Guo, and X. Li, “Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation,” Cell Metabolism, vol. 9, no. 4, pp. 327–338, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Yoshizaki, J. C. Milne, T. Imamura et al., “SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes,” Molecular and Cellular Biology, vol. 29, no. 5, pp. 1363–1374, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Cao, C. Liu, F. Wang, and H. Wang, “SIRT1 negatively regulates amyloid-beta-induced inflammation via the NF-κB pathway,” Brazilian Journal of Medical and Biological Research, vol. 46, no. 8, pp. 659–669, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. W. Wang, L. Bai, H. Qiao et al., “The protective effect of fenofibrate against TNF-α-induced CD40 expression through SIRT1-mediated deacetylation of NF-κB in endothelial cells,” Inflammation, vol. 37, no. 1, pp. 177–185, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. C. D. S. Costa, F. Rohden, T. O. Hammes et al., “Resveratrol upregulated SIRT1, FOXO1, and adiponectin and downregulated PPARγ1-3 mRNA expression in human visceral adipocytes,” Obesity Surgery, vol. 21, no. 3, pp. 356–361, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. F. Salamone, F. Galvano, F. Cappello, A. Mangiameli, I. Barbagallo, and G. Li Volti, “Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis,” Translational Research, vol. 159, no. 6, pp. 477–486, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Loguercio, P. Andreone, C. Brisc et al., “Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial,” Free Radical Biology and Medicine, vol. 52, no. 9, pp. 1658–1665, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. H.-Z. Ying, Y.-H. Liu, B. Yu, Z.-Y. Wang, J.-N. Zang, and C.-H. Yu, “Dietary quercetin ameliorates nonalcoholic steatohepatitis induced by a high-fat diet in gerbils,” Food and Chemical Toxicology, vol. 52, pp. 53–60, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. H. Tsuchiya, Y. Ebata, T. Sakabe, S. Hama, K. Kogure, and G. Shiota, “High-fat, high-fructose diet induces hepatic iron overload via a hepcidin-independent mechanism prior to the onset of liver steatosis and insulin resistance in mice,” Metabolism: Clinical and Experimental, vol. 62, no. 1, pp. 62–69, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Malhi and G. J. Gores, “Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease,” Seminars in Liver Disease, vol. 28, no. 4, pp. 360–369, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. P. Hwang, H. G. Kim, J. H. Choi et al., “S-Allyl cysteine attenuates free fatty acid-induced lipogenesis in human HepG2 cells through activation of the AMP-activated protein kinase-dependent pathway,” The Journal of Nutritional Biochemistry, vol. 24, no. 8, pp. 1469–1478, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. J. T. Rodgers and P. Puigserver, “Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 31, pp. 12861–12866, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Y. Kim, J. H. Lim, H. H. Youn et al., “Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1α axis in db/db mice,” Diabetologia, vol. 56, no. 1, pp. 204–217, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. S. K. Panchal, H. Poudyal, and L. Brown, “Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats,” Journal of Nutrition, vol. 142, no. 6, pp. 1026–1032, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. J. Dong, X. Zhang, L. Zhang et al., “Quercetin reduces obesity-associated ATM infiltration and inflammation in mice: a mechanism including AMPKα1/SIRT,” Journal of Lipid Research, vol. 55, no. 3, pp. 363–374, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. J. H. Yang, S. C. Kim, B. Y. Shin et al., “O-methylated flavonol isorhamnetin prevents acute inflammation through blocking of NF-κB activation,” Food and Chemical Toxicology, vol. 59, pp. 362–372, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. X. Hong, H. Tang, L. Wu, and A. Li, “Protective effects of the Alisma orientalis extract on the experimental nonalcoholic fatty liver disease,” Journal of Pharmacy and Pharmacology, vol. 58, no. 10, pp. 1391–1398, 2006. View at Publisher · View at Google Scholar · View at Scopus